Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreen Co. (WBA) has completed its transition to a private company following its acquisition by Sycamore Partners, with Stefano Pessina and family reinvesting 100% of their interests. The company has appointed Mike Motz as the new CEO, replacing Tim Wentworth, while John Lederer has been named Executive Chairman.
Motz, formerly CEO of Staples US Retail and President of Shoppers Drug Mart, brings significant retail and operational experience to guide Walgreens in its new phase. The transition marks a strategic shift focusing on the company's core pharmacy and retail platform, emphasizing customer experience and operational efficiency as a private entity.
Sycamore Partners has completed its acquisition of Walgreens Boots Alliance (WBA), with the Pessina family reinvesting 100% of their interests in the company. Under the deal terms, WBA shareholders will receive $11.45 per share in cash, plus potential additional payments of up to $3.00 per share from future VillageMD monetization.
Following the acquisition, WBA's portfolio companies including Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD will operate as separate standalone entities. As a result of the transaction, WBA's common stock has ceased trading and been delisted from the Nasdaq.
Blazing Star Merger Sub, Inc. has announced the final results of its tender offer for Walgreens Boots Alliance (NASDAQ: WBA) notes across multiple series. The tender offer, which expired on August 27, 2025, received significant participation across all note series, with acceptance rates ranging from 85% to 98% of outstanding principal amounts.
The tender offer includes WBA's notes due between 2025 and 2050, with interest rates ranging from 2.125% to 8.125%, and Walgreen Co.'s 4.400% notes due 2042. The settlement is expected on August 28, 2025. This tender offer is conditional upon the closing of WBA's merger with Blazing Star Parent, LLC, where WBA will become a wholly-owned subsidiary of the parent company.
Blazing Star Merger Sub has extended the expiration time for its tender offer and consent solicitation for Walgreens Boots Alliance (NASDAQ: WBA) notes. The expiration time has been moved from August 26 to August 27, 2025, 5:00 PM ET. The settlement date remains August 28, 2025.
The tender offer covers ten different series of notes with various interest rates and maturities, including notes from both WBA and Walgreen Co. Significant portions of each note series have already been tendered, with participation rates ranging from 85% to 98% across different series.
This tender offer is connected to the previously announced merger agreement dated March 6, 2025, where Blazing Star Parent will acquire WBA. The withdrawal deadline of August 4, 2025, has already passed, and tendered notes cannot be withdrawn.
Blazing Star Merger Sub, Inc. announced an extension of the expiration time and settlement date for the previously announced tender offer and consent solicitation related to Walgreens Boots Alliance (NASDAQ: WBA) notes. The expiration time has been extended from August 21, 2025, to 5:00 p.m., New York City time, on August 26, 2025, with settlement now scheduled for August 28, 2025.
The tender offer covers multiple series of senior notes with various interest rates and maturities ranging from 2025 to 2050. Significant participation has been observed across all note series, with high tender rates including 89% of the 2029 Notes and 98% of the 2046 Notes. The tender offer is conditional upon the closing of WBA's merger with Blazing Star Parent, LLC, where WBA will become a wholly-owned subsidiary.
Walgreens Specialty Pharmacy (NYSE:WBA) has significantly expanded its limited distribution drug (LDD) network to 265 products, positioning itself as a leading specialty pharmacy network. As the largest independent specialty pharmacy not affiliated with a PBM, Walgreens can collaborate with any healthcare partner.
The expansion comes as specialty drugs represent 75% of new drugs in development. Notable 2025 additions include Yeztugo for HIV prevention, Nemluvio for atopic dermatitis and prurigo nodularis, and Imkeldi for certain cancers. The company's comprehensive support team includes specialty pharmacists, nurses, patient advocates, and insurance specialists.
Blazing Star Merger Sub has extended the expiration time and settlement date for the previously announced tender offer and consent solicitation for Walgreens Boots Alliance (NASDAQ: WBA) notes. The expiration time has been extended to 5:00 p.m., New York City time, on August 21, 2025, with settlement now scheduled for August 26, 2025.
The tender offer covers multiple series of senior notes with various interest rates and maturities ranging from 2025 to 2050. Significant portions of each note series have already been tendered, with participation rates ranging from 84.7% to 98.1% across different note series. The tender offer is conditional upon the closing of WBA's acquisition by Blazing Star Parent, LLC, where WBA will become a wholly-owned subsidiary.
Blazing Star Merger Sub, Inc. has announced pricing terms for tender offers for Walgreens Boots Alliance's (NASDAQ: WBA) multiple series of senior notes, including notes due from 2025 to 2050, and Walgreen Co.'s 2042 notes. The tender offers are part of WBA's previously announced merger agreement with Blazing Star Parent, LLC.
The early tender results show significant participation across all note series, with the total consideration ranging from £997.73 to £1,074.10 per £1,000 principal amount. The tender offer expires on August 18, 2025, with settlement scheduled for August 19, 2025. Requisite consents have been received for all note series, and supplemental indentures have been executed.
Blazing Star Merger Sub, Inc. announced early tender results for Walgreens Boots Alliance (NASDAQ: WBA)'s previously announced cash tender offers and consent solicitation for multiple series of senior notes. As of the Early Tender Deadline on August 4, 2025, the company received significant participation across all note series, with tender rates ranging from 83% to 98% of outstanding principal amounts.
The tender offer is connected to WBA's pending acquisition through a merger agreement dated March 6, 2025, where Blazing Star Parent, LLC will acquire WBA. The company has received the requisite consents for proposed amendments to the indentures. The tender offer is scheduled to expire on August 18, 2025, with settlement expected on August 19, 2025, coinciding with the merger closing.
Walgreens (NYSE:WBA) has launched nationwide flu shot appointments for individuals aged three and older, with both walk-in and scheduled vaccination options available. The company is enhancing its vaccination services with digital check-in features and the ability to schedule multiple vaccines in a single visit for up to four people.
Starting August 1, myWalgreens members will receive 20% off their next eligible purchase with any vaccine. The announcement comes as pharmacy-administered flu vaccines nearly doubled to 38 million doses in 2024-2025 compared to 22 million doses in medical offices. The CDC data indicates that the 2024-2025 flu season was notably severe, marking the first such occurrence since 2017-2018.
FAQ
What is the current stock price of Walgreen Boots (WBA)?
What is the market cap of Walgreen Boots (WBA)?
